Ambition Zero Carbon

Bringing forward decarbonisation plans by more than a decade

In our ‘Ambition Zero Carbon’ programme, we commit to have zero carbon emissions from operations across the world by 2025 and ensure our entire value chain is carbon negative by 2030, bringing forward decarbonisation plans by more than a decade.


The programme accelerates our existing science-based targets, doubling energy productivity and using renewable energy for both power and heat, as well as switching to 100% electric vehicle fleet five years ahead of schedule. Ambition Zero Carbon sets out to make AstraZeneca’s operations responsible for zero carbon emissions without relying on offset schemes to reach zero emissions on aggregate.

We will invest up to $1bn to achieve these goals and to develop the next-generation respiratory inhalers with near-zero Global Warming Potential (GWP) propellants. We expect the propellant used in our next-generation pMDI to have an environmental footprint, measured as GWP, that is 90-99% lower than propellants used in older pMDIs.1

Also included in today’s plan, is ‘AZ Forest’, a 50-million tree reforestation initiative that will be rolled out over the next five years. In partnership with local governments and One Tree Planted, a non-profit organisation focused on global reforestation, the first trees will go into the ground in Australia in February 2020, with France, Indonesia and other countries to follow. This initiative supports the World Economic Forum’s (WEF) newly launched ‘ – The Champions for a Trillion Trees’ platform.

As a further step to help shape policy and find cross-industry solutions to rapidly decarbonise the global economy, Pascal Soriot, Chief Executive Officer, has joined the Sustainable Markets Council (SMC). The Council was established by His Royal Highness, the Prince of Wales, with the support of the World Economic Forum, as an advisory body of public-private-philanthropic leaders to drive sustainable solutions in line with the United Nation’s Sustainable Development Goals.

Climate change is an urgent threat to public health, the environment and the sustainability of the global economy. Since 2015, we have reduced our greenhouse gas emissions from operations by almost a third and our water consumption by almost one fifth. But now is the time to act even faster and redouble our efforts. The commitments AstraZeneca has made today as part of our ‘Ambition Zero Carbon’ strategy will enable us to speed up the reduction of our Company’s impact on climate and inspire collaboration at a global level to effect policy change.

Pascal Soriot Chief Executive Officer

We congratulate AstraZeneca for responding to the climate emergency and raising the ambition of their science-based targets, which were already in line with the Paris Agreement’s most ambitious goal – to limit warming to 1.5 degrees. As the impact of climate change is felt by more and more communities across the globe, AstraZeneca’s collaborative approach to scale the impact of a science-based approach across their value chain is exactly what is needed.

Alexander Farsan Global Lead of Science Based Targets, WWF International and Steering Committee member of the Science Based Targets initiative

Ambition Zero Carbon

Achievements and recent recognitions

CDP A List for Climate Change

On 20 January 2020, AstraZeneca was commended for its climate action, achieving a place on global environmental impact non-profit CDP's prestigious ‘A List’ for climate change, based on the company’s climate reporting in 2019, for the fourth consecutive year. AstraZeneca was recognized for its actions to cut emissions, mitigate climate risks and develop the low-carbon economy, based on the data submitted by the company through CDP’s 2019 climate change questionnaire. The Company is one of a small number of high-performing companies out of thousands that were scored.

Corporate Knights World’s 100 Most Sustainable Corporations

On 21 January 2020, AstraZeneca was also recognised by Corporate Knights as one of the world’s 100 most sustainable companies out of more than 7,000 companies assessed, ranking 56th overall.



1. AstraZeneca. pMDI Sustainability: Lifecycle Assessment Results. May 2019. Internal.



  • Sustainability